Abstract
Nausea and vomiting are two of the most severe problems for patients treated with chemotherapy. Until the late 1970s, nausea and vomiting induced by chemotherapy was an almost neglected research area. With the introduction of cisplatin, the cytotoxin with the highest emetic potential, research was stimulated and has now resulted in the development of two new classes of antiemetics, the serotonin and neurokinin antagonists. A large number of trials have fine-tuned antiemetic therapy and made evidence-based recommendations possible for the majority of patients receiving chemotherapy. This Review discusses the pathophysiology of nausea and vomiting, the development of antiemetics, highlights some of the newest antiemetics, and finally summarizes recommendations from the evidence-based guidelines developed by the Multinational Association of Supportive Care in Cancer.
Key Points
-
Although the pathophysiology of nausea and vomiting is still not completely elucidated, the increased understanding of the basic mechanisms has advanced the clinical development of antiemetics
-
Corticosteroids are useful antiemetics; recently, the development of serotonin antagonists and the neurokinin antagonist, aprepitant, have resulted in a significant decrease in the number of vomiting episodes experienced by patients receiving emetogenic chemotherapy
-
Treatment of the nausea associated with emetogenic chemotherapy is still a major problem
-
Evidence-based guidelines for antiemetic treatment have been developed and are updated on a regular basis; implementation of these guidelines should be encouraged
-
Promising results from phase II studies, of dexamethasone plus different two-drug combinations of the new serotonin antagonist, palonosetron, the neurokinin antagonist, aprepitant, and the antipsychotic agent, olanzapine, require verification in large randomized trials
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Landing BH et al. (1949) Systemic pathological effects of nitrogen mustards, and a comparison of toxicity, chemical structure and cytotoxic effect, with reference to the chemotherapy of tumors. Cancer 2: 1055–1066
Coates A et al. (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203–208
Thumas LJ (1892) Ueber das Brechcentrum und über die wirkung einiger pharmakologischer Mittel auf dasselbe. Archieves für Patologische Anatomie 123: 44–69
Hatcher RA and Weiss S (1923) Studies on vomiting. J Pharmacol Exp Ther 22: 139–193
Wang SC and Borison HL (1952) A new concept of organization of the central emetic mechanism: recent studies on sites of action of apomorphine, copper sulphate and cardiac glycosides. Gastroenterology 22: 1–12
Borison HL and Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193–230
Lindstrom PA and Brizzee KR (1962) Relief of intractable vomiting from surgical lesions in the area postrema. J Neurosurg 19: 228–236
McCarthy LE and Borison HL (1984) Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 68: 401–404
Smith WL et al. (1988) The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 40: 142–143
Miller AD and Wilson VJ (1983) “Vomiting center” reanalyzed: an electrical stimulation study. Brain Res 270: 154–158
Carpenter DO (1990) Neural mechanisms of emesis. Can J Physiol Pharmacol 68: 230–236
Miller AD et al. (1994) Brain areas essential or non-essential for emesis. Brain Res 647: 255–264
Yoshida N et al. (1995) A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog. Life Sci 57: PL347–PL350
Yoshikawa T et al. (1996) Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 301: 143–149
Moertel CG et al. (1963) A controlled clinical evaluation of antiemetic drugs. JAMA 186: 116–118
Rapport MM et al. (1948) Crystalline serotonin. Science 108: 329–330
Gaddum JH and Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol. Chemother 12: 323–328
Peroutka SJ and Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16: 687–699
Bradley PB et al. (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576
Hoyer D et al. (1994) International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Exper Ther 46: 157–203
Barrera NP et al. (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci USA 102: 12595–12600
Kilpatrick GJ et al. (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330: 746–748
Pratt GD et al. (1990) Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. TIPS 11: 135–137
Fozard JR and Mobarok ALI A (1978) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49: 109–112
Gralla RJ et al. (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 305: 905–909
Fozard JR (1984) MDL 72222, a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36–44
Miner WD and Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497–499
Costall B et al. (1986) 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959–961
Leibundgut U and Lancranjan I (1987) First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 329: 1198
Von Euler VS and Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931: 577–583
Chang M and Leeman SE (1970) Isolation of sialogogic peptide from bovine hypothalamic tissue and its characteristic as substance P. J Biol Chem 245: 4784–4790
Leander S et al. (1981) A specific substance P antagonist blocks smooth muscle contractions induced by non-cholinergic, non-adrenergic nerve stimulation. Nature 294: 467–469
Snider RM et al. (1991) A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251: 435–437
Tattersall FD et al. (1993) The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250: R5–R6
Kris MG et al. (1997) Use of a NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89: 817–818
Tsukuda M et al. (1995) Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Eur J Cancer 31A: 1647–1649
Longo DL et al. (1982) Results of a randomized, double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat Rep 66: 1975–1976
Herrstedt J et al. (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6: 204–214
Baker JJ et al. (1979) Letter. N Eng J Med 301: 728
Dana BW et al. (1985) Dexamethasone vs. placebo for cisplatin-induced emesis: a randomized cross-over trial. Am J Clin Oncol 8: 426–428
Allan SG et al. (1984) Deaxamethasone and high-dose metoclopramide: efficacy in controlling cisplatin-induced nausea and vomiting. BMJ 289: 878–879
Roila F et al. (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter, randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9: 675–678
Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5
Roila F et al. (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13: 104–108
Kris MG et al. (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic risk chemotherapy. Support Care Cancer 13: 85–96
Kris MG et al. (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 55: 527–534
Cunningham D et al. (1987) Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 329: 1461–1463
Marty M et al. (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816–821
De Mulder PHM et al. (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113: 834–840
Hainsworth J et al. (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9: 721–728
Bonneterre J et al. (1990) A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063–1069
Kaasa S et al. (1990) A comparison of ondansetron and metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 26: 311–314
Marschner NW et al. (1991) Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137–1140
Jones AL et al. (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483–487
Warr D et al. (1993) A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer 29A: 33–36
Warr D et al. (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83: 1169–1173
Geling O and Eichler H-G (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23: 1289–1294
Hesketh PJ et al. (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12: 596–600
Herrstedt J et al. (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076–1080
Herrstedt J et al. (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during cisplatinum-based chemotherapy in patients with cancer. J Clin Oncol 15: 1690–1696
Antiemetic Subcommittee of The Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9: 811–819
Jordan K et al. (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61: 162–175
Gralla RJ et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14: 1570–1577
Eisenberg P et al. (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98: 2473–2482
Aapro MS et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17: 1441–1449
Cocquyt V et al. (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37: 835–842
Navari RM et al. (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340: 190–195
Van Belle S et al. (2002) Prevention of cisplatin-induced acute and delayed emesis by selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94: 3032–3041
Campos D et al. (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19: 1759–1767
Chawla SP et al. (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97: 2290–3000
Poli-Bigelli S et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97: 3090–3098
Hesketh PJ et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin.The aprepitant 052 study group. J Clin Oncol 21: 4112–4119
Warr DG et al. (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23: 2822–2830
Schmoll HJ et al. (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17: 4112–4119
Hesketh PJ et al. (1999) Randomized phase II study of the neurokinin-1 receptor antagonist, CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338–343
De Witt R et al. (2004) The oral NK-1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of 2 randomized, placebo-controlled phase III trials. Eur J Cancer 40: 403–410
Herrstedt J et al. (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately emetogenic chemotherapy. Cancer 104: 1548–1555
Nygren P et al. (2005) Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 55: 609–616
Apornwirat W et al. (2006) Multicenter, randomized, double-blind ondansetron controlled, dose-ranging parallel group trial of the neurokinin-1 receptor antagonist casopitant mesylate for chemotherapy-induced nausea/vomiting in patients receiving moderately emetogenic chemotherapy [abstract]. J Clin Oncol 24: 471s
Rolski J et al. (2006) Randomized phase II trial of the neurokinin-1 receptor antagonist casopitant mesylate with ondansetron/dexamethasone for chemotherapy-induced nausea/vomiting in patients receiving highly emetogenic chemotherapy [abstract]. J Clin Oncol 24: 471s
Navari RM et al. (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15: 1285–1291
Mandala M et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 13: 375–380
Rudd JA et al. (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392: 79–83
Roila F et al. (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17: 20–28
Kris MG et al. (2006) ASCO Guidelines for Antiemetics in Oncology: Update 2006. J Clin Oncol 24: 2932–2947
Ballatori E et al. (1997) Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 5: 269–273
Dranitsaris G et al. (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9: 611–618
Nolte MJ et al. (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for the development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16: 771–778
Grunberg SM et al. (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100: 2261–2288
Grote T et al. (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support Oncol 4: 403–408
Grunberg SM et al. (2006) Prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with a 1-day 3-drug antiemetic regimen—preliminary report [abstract]. Support Care Cancer 14: 596
Kangawa H et al. (1983) Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun 114: 533–540
Kimura S et al. (1983) Novel neuropeptides, neurokinin A and B isolated from porcine spinal cord. Proc Jpn Acad 59B: 101–104
Tatemoto K et al. (1985) Neuropeptide K: isolation, structure and biological activities of a novel tachykinin. Biochem Biophys Res Commun 128: 947–953
Kage R et al. (1988) Neuropeptide γ: a peptide isolated from rabbit intestine that is derived from χ-preprotachykinin. J Neurochem 50: 1412–1417
Maggi CA et al. (1993) Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 13: 23–93
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author is a Consultant for GlaxoSmithKline, Helsinn, Merck and Schering—Plough, and is on the Speakers bureau for Merck. He also receives research/grant support from GlaxoSmithKline and Merck.
Rights and permissions
About this article
Cite this article
Herrstedt, J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Rev Clin Oncol 5, 32–43 (2008). https://doi.org/10.1038/ncponc1021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1021
This article is cited by
-
A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy
Medical Oncology (2017)
-
A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies
International Journal of Hematology (2015)
-
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study
Breast Cancer (2015)
-
Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant
Supportive Care in Cancer (2014)
-
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids
Cancer Chemotherapy and Pharmacology (2013)